Literature DB >> 32432143

Seroconversion of HBsAG coincides with hepatitis A super-infection: A case report.

Claudia Beisel1, Marylyn M Addo1, Julian Schulze Zur Wiesch2.   

Abstract

BACKGROUND: Hepatitis B virus (HBV) is a hepatotropic virus that can cause acute and chronic liver damage. According to the world health organization 257 million people are infected with chronic HBV infection worldwide. Super-infection with other hepadnaviruses, including hepatitis A virus (HAV), hepatitis C virus, hepatitis D virus, and hepatitis E virus is associated with increased risk of acute liver failure in patients with chronic HBV. CASE
SUMMARY: Here, we report a case of a 47-year old male patient with HBV-related compensated Child A cirrhosis, who presented with general fatigue, malaise and laboratory signs of acute hepatitis. Although the patient was regularly seen at a specialized university liver unit, the HAV vaccination status was unclear. Acute HAV super-infection was diagnosed by positive serological and polymerase chain reaction analysis. Following acute HAV super-infection, spontaneous HBsAg elimination and development of an anti-HBs titer were observed.
CONCLUSION: This case illustrates the importance of carefully checking the vaccination status. In our patient, unspecific immunological responses to HAV led to functional cure of HBV. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Acute hepatitis A infection; Case report; Chronic hepatitis B infection; Functional cure; HBsAg clearance; Liver cirrhosis

Year:  2020        PMID: 32432143      PMCID: PMC7211520          DOI: 10.12998/wjcc.v8.i9.1651

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  17 in total

1.  Hepatitis B virus clearance from serum and liver after acute hepatitis delta virus superinfection in chronic HBsAg carriers.

Authors:  G Pastore; L Monno; T Santantonio; G Angarano; M Milella; A Giannelli; J R Fiore
Journal:  J Med Virol       Date:  1990-08       Impact factor: 2.327

2.  Influence of chronic HBV infection on superimposed acute hepatitis E.

Authors:  Si-Hong Cheng; Li Mai; Feng-Qin Zhu; Xing-Fei Pan; Hai-Xia Sun; Hong Cao; Xin Shu; Wei-Min Ke; Gang Li; Qi-Huan Xu
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

Review 3.  Global Elimination of Chronic Hepatitis.

Authors:  David L Thomas
Journal:  N Engl J Med       Date:  2019-05-23       Impact factor: 91.245

Review 4.  Adaptive Immune Responses in Hepatitis A Virus and Hepatitis E Virus Infections.

Authors:  Christopher M Walker
Journal:  Cold Spring Harb Perspect Med       Date:  2019-09-03       Impact factor: 6.915

5.  Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen.

Authors:  Ahmad Samer Alawad; Sungyoung Auh; Daniel Suarez; Marc G Ghany
Journal:  Clin Gastroenterol Hepatol       Date:  2019-07-16       Impact factor: 11.382

Review 6.  Immune Response in Hepatitis B Virus Infection.

Authors:  Anthony Tan; Sarene Koh; Antonio Bertoletti
Journal:  Cold Spring Harb Perspect Med       Date:  2015-07-01       Impact factor: 6.915

7.  Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Anthony E Fiore; Annemarie Wasley; Beth P Bell
Journal:  MMWR Recomm Rep       Date:  2006-05-19

8.  Clinical analysis of patients suffering from chronic hepatitis B superinfected with other hepadnaviruses.

Authors:  Jia Fu; Dan Guo; Dandan Gao; Wenxiang Huang; Ziqiong Li; Bei Jia
Journal:  J Med Virol       Date:  2015-11-18       Impact factor: 2.327

9.  Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.

Authors:  Anna S Lok; Mark S Sulkowski; Jens J Kort; Ira Willner; K Rajender Reddy; Mitchell L Shiffman; Mohamed A Hassan; Brian L Pearlman; Federico Hinestrosa; Ira M Jacobson; Giuseppe Morelli; Joy A Peter; Monika Vainorius; Larry C Michael; Michael W Fried; Gary P Wang; Wenjing Lu; Lois Larsen; David R Nelson
Journal:  Gastroenterology       Date:  2019-08-08       Impact factor: 22.682

10.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013.

Authors:  Jeffrey D Stanaway; Abraham D Flaxman; Mohsen Naghavi; Christina Fitzmaurice; Theo Vos; Ibrahim Abubakar; Laith J Abu-Raddad; Reza Assadi; Neeraj Bhala; Benjamin Cowie; Mohammad H Forouzanfour; Justina Groeger; Khayriyyah Mohd Hanafiah; Kathryn H Jacobsen; Spencer L James; Jennifer MacLachlan; Reza Malekzadeh; Natasha K Martin; Ali A Mokdad; Ali H Mokdad; Christopher J L Murray; Dietrich Plass; Saleem Rana; David B Rein; Jan Hendrik Richardus; Juan Sanabria; Mete Saylan; Saeid Shahraz; Samuel So; Vasiliy V Vlassov; Elisabete Weiderpass; Steven T Wiersma; Mustafa Younis; Chuanhua Yu; Maysaa El Sayed Zaki; Graham S Cooke
Journal:  Lancet       Date:  2016-07-07       Impact factor: 79.321

View more
  3 in total

Review 1.  Immune Mechanisms Underlying Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients With Viral Coinfection.

Authors:  Shuling Wu; Wei Yi; Yuanjiao Gao; Wen Deng; Xiaoyue Bi; Yanjie Lin; Liu Yang; Yao Lu; Ruyu Liu; Min Chang; Ge Shen; Leiping Hu; Lu Zhang; Minghui Li; Yao Xie
Journal:  Front Immunol       Date:  2022-05-11       Impact factor: 8.786

Review 2.  Co-Occurrence of Hepatitis A Infection and Chronic Liver Disease.

Authors:  Tatsuo Kanda; Reina Sasaki; Ryota Masuzaki; Hiroshi Takahashi; Taku Mizutani; Naoki Matsumoto; Kazushige Nirei; Mitsuhiko Moriyama
Journal:  Int J Mol Sci       Date:  2020-09-02       Impact factor: 5.923

Review 3.  Chitosan-Based Nanoparticles Against Viral Infections.

Authors:  Homa Boroumand; Fereshteh Badie; Samaneh Mazaheri; Zeynab Sadat Seyedi; Javid Sadri Nahand; Majid Nejati; Hossein Bannazadeh Baghi; Mohammad Abbasi-Kolli; Bita Badehnoosh; Maryam Ghandali; Michael R Hamblin; Hamed Mirzaei
Journal:  Front Cell Infect Microbiol       Date:  2021-03-17       Impact factor: 5.293

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.